Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape. This is a video synopsis/summary of an ...

Brensocatib is the first approved therapy for non–cystic fibrosis bronchiectasis and the first dipeptidyl peptidase 1 inhibitor for neutrophil-mediated diseases. The ASPEN trial showed brensocatib ...

DPP-1 inhibitors and macrolides likely reduce the frequency of exacerbations in patients with non-cystic fibrosis bronchiectasis compared with placebo, a network meta-analysis shows.

BRONCHIECTASIS is protean in its expressions as it is sometimes obscure in its origin. The clinical picture varies in individual patients, but common to the severer cases is a history of harassing, ...

Please provide your email address to receive an email when new articles are posted on . Patients in this subgroup participated in the phase 3 ASPEN trial. Brensocatib given as 10 mg or 25 mg performed ...

FIRS organizations, including the American Thoracic Society, call for improving early detection of bronchiectasis. July 1, 2025 – According to the 2022 Global Impact of Respiratory Disease Report, the ...

Please provide your email address to receive an email when new articles are posted on . For adults with bronchiectasis, $82,545 was the highest annual health care cost observed in a systematic review.

CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic fibrosis bronchiectasis at its higher dose, a CT substudy of the ASPEN trial ...

Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 adults nationwide, is necessary to slow disease progression and help ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to educate people with bronchiectasis about how to better manage the disease.